SERA vs. BDSX, PSNL, CELC, CDNA, LUCD, CODX, TLIS, FLGT, CSTL, and VRDN
Should you be buying Sera Prognostics stock or one of its competitors? The main competitors of Sera Prognostics include Biodesix (BDSX), Personalis (PSNL), Celcuity (CELC), CareDx (CDNA), Lucid Diagnostics (LUCD), Co-Diagnostics (CODX), Talis Biomedical (TLIS), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), and Viridian Therapeutics (VRDN). These companies are all part of the "medical" sector.
Biodesix (NASDAQ:BDSX) and Sera Prognostics (NASDAQ:SERA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, community ranking, analyst recommendations and valuation.
Sera Prognostics has lower revenue, but higher earnings than Biodesix. Sera Prognostics is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.
21.0% of Biodesix shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 63.8% of Biodesix shares are owned by company insiders. Comparatively, 15.8% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Sera Prognostics had 3 more articles in the media than Biodesix. MarketBeat recorded 23 mentions for Sera Prognostics and 20 mentions for Biodesix. Sera Prognostics' average media sentiment score of 0.52 beat Biodesix's score of 0.24 indicating that Biodesix is being referred to more favorably in the media.
Biodesix received 17 more outperform votes than Sera Prognostics when rated by MarketBeat users. Likewise, 72.97% of users gave Biodesix an outperform vote while only 38.46% of users gave Sera Prognostics an outperform vote.
Biodesix presently has a consensus price target of $3.10, suggesting a potential upside of 107.36%. Sera Prognostics has a consensus price target of $2.75, suggesting a potential downside of 67.07%. Given Sera Prognostics' stronger consensus rating and higher probable upside, equities analysts clearly believe Biodesix is more favorable than Sera Prognostics.
Biodesix has a net margin of -85.80% compared to Biodesix's net margin of -11,843.79%. Biodesix's return on equity of -46.35% beat Sera Prognostics' return on equity.
Biodesix has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.
Summary
Biodesix beats Sera Prognostics on 11 of the 18 factors compared between the two stocks.
Get Sera Prognostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SERA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sera Prognostics Competitors List
Related Companies and Tools
